Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JBZ-001
- Development stage
- Phase 1
- Lead developer
- JBZ
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
JBZ-001 is an orally bioavailable small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH), the rate-limiting enzyme in the de novo pyrimidine nucleotide biosynthesis pathway. By inhibiting DHODH, JBZ-001 disrupts nucleotide production essential for cancer cell proliferation, leading to cytotoxic effects in tumor cells. The drug is being developed by Jabez Biosciences as a next-generation targeted therapy for advanced solid tumors and hematological malignancies, including non-Hodgkin lymphoma and acute myeloid leukemia (AML). Preclinical studies have shown robust anti-cancer activity and favorable safety profiles. As of mid-2025, JBZ-001 is undergoing Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and preliminary efficacy in patients with advanced cancers[1][2][3][5][6][7].
- Other names
- JBZ 001JBZ001JBZ-001
02
Targets
DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)
Beyond the preview
Go deeper on JBZ-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JBZ-001.